Ventricular restoration patch
Summary by NHIP
Ventricular restoration patch
The ventricular patch comprises a biocompatible sheet with a fixed continuous ring forming a central elongated region. This region maintains a length-to-width ratio of 4:1, with specific dimensions of 4 cm length and 1 cm width.
Claim Score by NHIP
Abstract
A ventricular patch to restore the ventricular architecture of the heart includes a sheet of biocompatible material having a generally oval configuration, and a continuous ring fixed to the sheet. The ring has a generally oval configuration similar to the generally oval configuration of the sheet of biocompatible material. The ring defines a central generally oval region of the patch inside the ring and a circumferential region of the patch outside of the ring. The central generally oval region has a major axis and a minor axis. The ratio of the major axis to the minor axis is about 4:1.

Term
Term ended
Expired 1 May 2018, 8.4 years ago.
- Priority
- Filed
- Granted
- Expired
- Today
14 claims: 6 independent, 8 dependent
- 1A ventricular patch to restore the ventricular architecture of the heart, comprising:a sheet of biocompatible material having a longitudinally elongated configuration;a continuous ring fixed to the sheet and having a longitudinally elongated configuration similar to the longitudinally elongated configuration of the sheet of biocompatible material, the ring defining a central longitudinally elongated region of the patch inside the ring and a circumferential region of the patch outside of the ring, the central longitudinally elongated region having a length and a width, the ratio of the length to the width being 4:1, wherein the ventricular patch is sized and configured to be positioned within the ventricle to restore the conical apex of the heart.
- 3A ventricular patch to restore the ventricular architecture of the heart, comprising:a sheet of biocompatible material having a longitudinally elongated configuration;a continuous ring fixed to the sheet and having a longitudinally elongated configuration similar to the longitudinally elongated configuration of the sheet of biocompatible material, the ring defining a central longitudinally elongated region of the patch inside the ring and a circumferential region of the patch outside of the ring, the central longitudinally elongated region having a length and a width, the ratio of the length to the width being greater than 2:1, wherein the ventricular patch is sized and configured to be positioned within the ventricle to restore the conical apex of the heart.
- 7A ventricular patch to restore the ventricular architecture of the heart, comprising:a sheet of biocompatible material having a longitudinally elongated configuration;a continuous ring fixed to the sheet and having a longitudinally elongated configuration similar to the longitudinally elongated configuration of the sheet of biocompatible material, the ring defining a central longitudinally elongated region of the patch inside the ring and a circumferential region of the patch outside of the ring, the central longitudinally elongated region having a length ranging from 2 cm to 8 cm, a width ranging from 0.5 cm to 1 cm, and the ratio of the length to the width being greater than 2:1, wherein the ventricular patch is sized and configured to be positioned within the ventricle to restore the conical apex of the heart.
- 8Broadest claimClaim Score 92, very broad(NHIP)A ventricular patch to restore the ventricular architecture of the heart, comprising:a sheet of biocompatible material having a longitudinally elongated configuration, a length, and a width, the ratio of the length to the width being 4:1, wherein the ventricular patch is sized and configured to be positioned within the ventricle to restore the conical apex of the heart.
- 10A ventricular patch to restore the ventricular architecture of the heart, comprising:a sheet of biocompatible material having a longitudinally elongated configuration, a length, and a width, the ratio of the length to the width being greater than 2:1, wherein the ventricular patch is sized and configured to be positioned within the ventricle to restore the conical apex of the heart.
- 14A ventricular patch to restore the ventricular architecture of the heart, comprising:a sheet of biocompatible material having a longitudinally elongated configuration with a length ranging from 2 cm to 8 cm, a width ranging from 0.5 cm to 1 cm, and the ratio of the length to the width being greater than 2:1, wherein the ventricular patch is sized and configured to be positioned within the ventricle to restore the conical apex of the heart.
Independent claims6
114 paragraphs in 4 sections, as filed
This is a continuation-in-part of pending prior application Ser. No. 09/481,755 filed on Jan. 11, 2000, which is a continuation of prior application Ser. No. 09/071,817 filed May 1, 1998 which issued as U.S. Pat. No. 6,024,096 on Feb. 15, 2000.
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to surgical methods and apparatus for addressing ischemic cardiomyopathy, and more specifically to methods and apparatus for restoring the architecture and normal function of a mammalian heart.
2. Discussion of the Prior Art
The function of a heart in an animal is primarily to deliver life-supporting oxygenated blood to tissue throughout the body. This function is accomplished in four stages, each relating to a particular chamber of the heart. Initially deoxygenated blood is received in the right auricle of the heart. This deoxygenated blood is pumped by the right ventricle of the heart to the lungs where the blood is oxygenated. The oxygenated blood is initially received in the left auricle of the heart and ultimately pumped by the left ventricle of the heart throughout the body. It can be seen that the left ventricular chamber of the heart is of particular importance in this process as it is relied upon to pump the oxygenated blood initially through a mitral valve into and ultimately throughout the entire vascular system.
A certain percentage of the blood in the left ventricle is pumped during each stroke of the heart. This pumped percentage, commonly referred to as the ejection fraction, is normally about sixty percent. It can be seen that in a heart having a left ventricular volume such as seventy milliliters, an ejection fraction of sixty percent would deliver approximately 42 milliliters of blood into the aorta. A heart with reduced left ventricular volume might have an ejection fraction of only 40% and provide a stroke volume of only 28 millimeters.
Realizing that the heart is part of the body tissue, and the heart muscle also requires oxygenated blood, it can be appreciated that the normal function of the heart is greatly upset by clotting or closure of the coronary arteries. When the coronary arteries are blocked, an associate portion of the heart muscle becomes oxygen-starved and begins to die. This is clinically referred to as a heart attack. Ischemic cardiomyopathy typically occurs as the rest of the heart dilates in an attempt to maintain the heart's output to the body.
As the ischemic area loses its contraction, the area of dilatation is restricted to the remaining muscle. The three regions of typical infarction include, 1) the anterior wall septum and anterolateral wall which are supplied by the anterior descending coronary artery; 2) the septum and inferior wall supplied by the left anterior artery and the right coronary artery which narrows due to the heart's elliptical shape; and 3) the lateral wall supplied by the circumflex artery which perfuses the lateral wall including the papillary muscle attachments to the ventricular wall.
As the ischemic cardiomyopathy progresses, the various structures of the heart are progressively involved including the septum, the apex and the anterolateral wall of the left ventricle. Within a particular wall, the blood starvation begins at the inside of the wall and progresses to the outside of the wall. It can be seen that addressing ischemic cardiomyopathy shortly after the heart attack can limit the detrimental effects to certain elements of the heart structure, as well as the inner most thicknesses of the walls defining those structures.
As a heart muscle is denied blood nourishment support, its ability to participate, let alone aid, in the cardiac pumping function, is greatly diminished and typically nil. Such muscle is commonly referred to as akinetic, meaning it does not move. In some cases the wall will form elastic scar tissue which tends to balloon in response to the pumping action. This muscle tissue is not only akinetic, in that it does not contribute to the pumping function, but it is in fact dyskinetic, in that it detracts from the pumping function.
The akinetic tissue will, in addition to not contracting, cause cardiac enlargement due to dilatation or loss of its contractile capacity. The dilatation will widen, and thereby change the fiber orientation of the remaining muscle in the left ventricle. This will make the ventricle spherical, and change it from the normal elliptical form which optimizes contraction.
The shape of the ventricle is normally elliptical or conical with an apex that allows a 60 degree fiber orientation of the muscle. This orientation ensures efficient development of intramuscular torsion to facilitate the pumping of blood. Compression of the left ventricular cavity occurs by torsional defamation which thickens the left ventricular wall. This increases progressively from the mid-ventricular wall to the apex. As a result, maintenance of the apical anchor is a central theme of cardiac contraction.
Perhaps the most notable symptom of ischemic cardiomyopathy is the reduction in the ejection fraction which may diminish, for example, from a normal sixty percent to only twenty percent. This results clinically in fatigue, and inability to do stressful activities, that require an increase in output of blood from the heart. The normal response of the heart to a reduction in ejection fraction is to increase the size of the ventricle so that the reduced percentage continues to deliver the same amount of oxygenated blood to the body. By way of example, the volume of the left ventricle may double in size. Furthermore, a dilated heart will tend to change its architecture from the normal conical or apical shape, to a generally spherical shape. The output of blood at rest is kept normal, but the capacity to increase output of blood during stress (i.e., exercise, walking) is reduced. Of course, this change in architecture has a dramatic effect on wall thickness, radius, and stress on the heart wall. In particular, it will be noted that absent the normal conical shape, the twisting motion at the apex, which can account for as much as one half of the pumping action, is lost. As a consequence, the more spherical architecture must rely almost totally on the lateral squeezing action to pump blood. This lateral squeezing action is inefficient and very different from the more efficient twisting action of the heart. The change in architecture of the heart will also typically change the structure and ability of the mitral valve to perform its function in the pumping process. Valvular insufficiency can also occur due to dilatation.
A major determinant of both cardiac oxygen requirement and efficiency is based upon a formula where stress or pressure is multiplied by the radius and divided by twice the thickness of the cardiac wall. Increasing stress reduces contractility or rejecting capacity, and raises energy requirements in the remaining contracting muscle. As the shape changes from elliptical to spherical, wall stress increases thereby demanding higher energy from the remaining cardiac muscle. This dilation, which occurs anteriorly, effects the septum, apex and anterolateral wall. Thus, the normally oval apex becomes more spherical due to 1) a loss of infarcted muscle, and 2) dilation of the remaining contracting muscle.
Although the dilated heart may be capable of sustaining life, it is significantly stressed and rapidly approaches a stage where it can no longer pump blood effectively. In this stage, commonly referred to as congestive heart failure, the heart becomes distended and is generally incapable of pumping blood returning from the lungs. This further results in lung congestion and fatigue. Congestive heart failure is a major cause of death and disability in the United States where approximately 400,000 cases occur annually.
Following coronary occlusion, successful acute reperfusion by thrombolysis, (clot dissolution) percutaneous angioplasty, or urgent surgery can decrease early mortality by reducing arrhythmias and cardiogenic shock. It is also known that addressing ischemic cardiomyopathy in the acute phase, for example with reperfusion, may salvage the epicardial surface. Although the myocardium may be rendered akinetic, at least it is not dyskinetic. Post-infarction surgical revascularization can be directed at remote viable muscle to reduce ischemia. However, it does not address the anatomical consequences of the akinetic region of the heart that is scarred. Despite these techniques for monitoring ischemia, cardiac dilation and subsequent heart failure continue to occur in approximately fifty percent of post-infarction patients discharged from the hospital.
The distribution of heart failure is more common with occlusion of the left anterior descending coronary artery (LAD) due to its perfusion of the apex. But, this can also occur with inferior infarction, especially if there is inadequate blood supply to the apex due to 1) prior damage to the left anterior descending artery, or 2) inadequate blood supply due to stenosis or poor function. In general, the distribution of ischemia is 45% anterior, 40% inferior, and 15% circumflex. However, the incidence of congestive heart failure is more common in the anterior infarction.
Various surgical approaches have been taken primarily to reduce the ventricular volume. This is also intended to increase the ejection fraction of the heart. In accordance with one procedure, viable muscle is removed from the heart in an attempt to merely reduce its volume. This procedure, which is typically accomplished on a beating heart, has been used for hearts that have not experienced coronary disease, but nevertheless, have dilated due to leaking heart valves. Other attempts have been made to remove the scarred portion of the heart and to close the resulting incision. This has also had the effect of reducing the ventricular volume.
In a further procedure, a round, circular patch has been proposed for placement typically in the lateral ventricular wall. Unfortunately, providing the patch with a circular shape has allowed the dilated heart to remain somewhat enlarged with a thin and over-stressed wall section. The exact placement of the patch has been visually determined using only a visual indication where the typically white scar tissue meets the typically red normal tissue. Location of the patch has been facilitated in a further procedure where a continuous suture has been placed around the ventricular wall to define a neck for receiving the patch. The neck has been formed in the white scar tissue rather than the soft viable muscle. This procedure has relied on cardioplegia methods to stop the beating of the heart and to aid in suture placement.
In the past, the patch has been provided with a fixed or semi-rigid wall which has prevented the muscle from becoming reduced to an apical anchor which facilitates the twisting motion. The patches have had a fixed planar configuration which have prevented the lateral muscle from coapting to form an apex.
These surgical procedures have been met with some success as the ejection fraction has been increased, for example, from twenty-four percent to forty-two percent. However, despite this level of success, little attention has been paid to myocardial protection, the potential for monitoring the writhing action associated with apical structure, or the preferred structure for the patch. Failure to protect the heart during restoration of the segment has increased hospital mortality, morbidity, and irreversibly damaged some normal muscle needed to maintain the heart's output.
SUMMARY OF THE INVENTION
An aspect of the invention involves a ventricular patch to restore the ventricular architecture of the heart. The ventricular patch includes a sheet of biocompatible material having a generally oval configuration, and a continuous ring fixed to the sheet. The ring has a generally oval configuration similar to the generally oval configuration of the sheet of biocompatible material. The ring defines a central generally oval region of the patch inside the ring and a circumferential region of the patch outside of the ring. The central generally oval region has a major axis and a minor axis. The ratio of the major axis to the minor axis is about 4:1. In a preferred implementation, the central generally oval region has a major axis of about 4 cm and a minor axis of about 1 cm.
Another aspect of the invention involves a ventricular patch to restore the ventricular architecture of the heart. The ventricular patch includes a sheet of biocompatible material having a generally oval configuration and a continuous ring fixed to the sheet. The continuous ring includes a generally oval configuration similar to the generally oval configuration of the sheet of biocompatible material, and defines a central generally oval region of the patch inside the ring and a circumferential region of the patch outside of the ring. The central generally oval region has a major axis and a minor axis. The ratio of the major axis to the minor axis is at least about 2:1.
Another aspect of the invention involves a ventricular patch to restore the ventricular architecture of the heart. The ventricular patch includes a sheet of biocompatible material having a generally oval configuration, and a continuous ring fixed to the sheet. The ring has a generally oval configuration similar to the generally oval configuration of the sheet of biocompatible material. The ring defines a central generally oval region of the patch inside the ring and a circumferential region of the patch outside of the ring. The central generally oval region has a major axis ranging from about 2 cm to about 8 cm and a minor axis ranging from about 0.5 cm to about 1 cm.
A further aspect of the invention involves a ventricular patch to restore the ventricular architecture of the heart. The ventricular patch includes a sheet of biocompatible material having a generally oval region with a major axis and a minor axis. The ratio of the major axis to the minor axis is about 4:1. In a preferred implementation, the generally oval region has a major axis of about 4 cm and a minor axis of about 1 cm.
A still further aspect of the invention involves a ventricular patch to restore the ventricular architecture of the heart. The ventricular patch includes a sheet of biocompatible material having a generally oval region with a major axis and a minor axis. The ratio of the major axis to the minor axis is at least about 2:1.
A yet further aspect of the invention involves a ventricular patch to restore the ventricular architecture of the heart. The ventricular patch includes a sheet of biocompatible material having a generally oval region with a major axis ranging from about 2 cm to about 8 cm and a minor axis ranging from about 0.5 cm to about 1 cm.
These and other features and advantages of the invention will become more apparent with a description of preferred embodiments and reference to the associated drawings.
DESCRIPTION OF THE DRAWINGS
FIG. 1 is a perspective view of the abdominal cavity of a human body showing the heart in cross section;
FIG. 2 is a front plan view of the heart showing coronary arteries which feed the septum, apex and lateral wall of the myocardium;
FIG. 3 is a axial cross section view of the ventricular portions of the heart illustrating a dilated, generally spherical left ventricle;
FIG. 4 is an anterior elevation view of the heart with an incision into the left ventricle through dyskinetic scar tissue;
FIG. 5 is an anterior elevation view similar to FIG. 4 where the incision is made in marbled akinetic tissue;
FIG. 6 is an anterior elevation view similar to FIG. 5 illustrating the incision made in normal-looking akinetic tissue;
FIG. 7 is a axial cross section view of the left ventricle showing the surgeon's hand palpating the myocardium to define an imaginary circumferential line of separation between viable and akinetic tissue;
FIG. 8 is a axial cross section view similar to FIG. 7 illustrating the palpating heart and a preferred zone of placement for a patch associated with the present invention;
FIG. 9 is an anterior elevation view similar to FIG. <b>4</b> and illustrating placement of a Fontan stitch in the ventricular wall;
FIG. 10 is an axial cross section view illustrating a Fontan neck created by the Fontan stitch;
FIG. 11 is a side elevation view of the opening illustrated in FIG. 9 with the Fontan suture tightened to facilitate the natural oval formation of the opening;
FIG. 12A is a plan view of sheet material included in one embodiment of the patch associated with the present invention;
FIG. 12B is a cross section view taken along lines <b>12</b>B—<b>12</b>B of FIG. <b>12</b>A and illustrating the sheet material in a concave configuration;
FIG. 13 is a top plan view of a ring associated with the patch of the present invention;
FIG. 14 is a circumferential cross section taken along lines <b>14</b>—<b>14</b> of FIG. 13;
FIG. 15 is a top plan view showing the sheet material and ring combined to form one embodiment of the patch of the present invention;
FIG. 16 is a cross section view of the patch taken along lines <b>16</b>—<b>16</b> of FIG. 15;
FIG. 17 is a cross section view similar to FIG. <b>12</b>B and illustrating the sheet material in a convex configuration;
FIG. 18 is a cross section view similar to FIG. <b>16</b> and illustrating the ring disposed on a concave surface of the sheet material;
FIG. 19 is a cross section view similar to FIG. <b>18</b> and illustrating the ring sandwiched between two pieces of the sheet material;
FIG. 20 is a cross section view similar to FIG. <b>19</b> and illustrating the ring sandwiched between two pieces of material, but having only a single layer in the center of the patch;
FIG. 21 is an anterior elevation view similar to FIG. <b>11</b> and illustrating the placement of pledgeted, interrupted sutures engaging the patch in a remote location;
FIG. 22A is an axial cross section view of the left ventricle illustrating the patch being moved along the interrupted sutures from the remote location to the Fontan neck;
FIG. 22B is a perspective view similar to FIG. <b>21</b> and illustrating an alternative method for placement of interrupted sutures;
FIG. 23 is an axial cross section view similar to FIG. <b>22</b> and illustrating the patch in its final disposition against the Fontan neck, and further illustrating use of the hemostatic rim to control bleeding;
FIG. 24 is an axial cross section view of the ventricular portion of the heart, with the patch mounted in place, the ventricle wall restored to its apical configuration, and the lateral ventricular wall closed in overlapping relationship with the septum wall next to the patch;
DESCRIPTION OF PREFERRED EMBODIMENTS AND BEST MODE OF THE INVENTION
Abdominal portions of the human body are illustrated in FIG. <b>1</b> and designated by the reference numeral <b>10</b>. The body <b>10</b> is merely representative of any mammalian body having a heart <b>12</b> which pumps blood containing nutrients and oxygen, to vitalize tissue in all areas of the body <b>10</b>. Other organs of particular importance to this blood circulation process include the lungs <b>14</b> and <b>16</b>, and the vasculature of the body <b>10</b> including arteries which carry blood away from the heart <b>12</b> and veins which return blood to the heart <b>12</b>.
The heart <b>12</b> typically includes four chambers, a right auricle <b>18</b>, a right ventricle <b>21</b>, a left auricle <b>23</b> and a left ventricle <b>25</b>. In general, the auricles <b>18</b> and <b>23</b> are receiving chambers and the ventricles <b>21</b> and <b>25</b> are pumping chambers. Each of these chambers <b>18</b>-<b>25</b> is associated with a respective function of the heart <b>12</b>. For example, it is the purpose of the right auricle <b>18</b> to receive the deoxygenated blood returning in the veins of the body <b>10</b>, such as the femoral vein <b>27</b>. From the right auricle <b>18</b>, the deoxygenated blood passes into the right ventricle <b>21</b> from which it is pumped through a pulmonary artery <b>30</b> to the lungs <b>14</b> and <b>16</b>.
Within the lungs <b>14</b> and <b>16</b>, the deoxygenated blood is reoxygenated and returned to the left auricle <b>23</b> of the heart <b>12</b> through a pulmonary vein <b>32</b>. From this chamber, the oxygenated blood passes through a mitral valve <b>34</b> into the left ventricle <b>25</b>. With each beat of the heart <b>12</b>, the left ventricle <b>25</b> contracts pumping the oxygenated blood into the arteries of the body, such as the femoral artery <b>36</b>.
The shape of the normal heart <b>12</b> is of particular interest as it dramatically affects the way that the blood is pumped. It will be noted, for example, that the left ventricle <b>25</b>, which is the primary pumping chamber, is somewhat elliptical, conical or apical in shape in that it is longer than it is wide and descends from a base <b>35</b> with a decreasing cross-sectional circumference, to a point or apex <b>37</b>. The left ventricle <b>25</b> is further defined by a lateral ventricle wall <b>38</b>, and a septum <b>41</b> which extends between the atrium <b>18</b>, <b>23</b>, and between the ventricles <b>21</b>, <b>25</b>. The mitral valve <b>34</b> is situated in an antero-ventricular junction <b>42</b> which extends laterally between the atrium <b>18</b>, <b>23</b>, and ventricles <b>21</b>, <b>25</b>. The “base” of the inferior muscle is also in this general location. This wide base <b>35</b> extends to the apex <b>37</b> on the inferior cardiac surface. In the area of the base <b>35</b>, the muscle is relatively flat or slightly spherical compared to the curvilinear form in the anterior wall. The muscle fiber orientation is maintained at approximately 60 degrees from base <b>35</b> to apex <b>37</b> to maintain the torsional gradient which facilitates ejection. This orientation of fibers changes to accentuate ejection, with less twisting at the base <b>35</b> and more twisting at the apex <b>37</b>.
On the backside, the heart <b>12</b> has an inferior wall that is not curved or linear, but rather flat or slightly spherical in configuration. This inferior wall extends from the antero-ventricular junction <b>42</b>, at the wide area of the heart, toward the apex <b>37</b>.
The pumping of the blood from the left ventricle <b>25</b> is accomplished by two types of motion. One of these motions is a simple squeezing motion which occurs between the lateral wall <b>38</b> and the septum <b>41</b> as illustrated by the arrows <b>43</b> and <b>45</b>, respectively. The squeezing motion occurs as a result of a thickening of the muscle fibers in the myocardium. This compresses the blood in the ventricle chamber <b>25</b> and ejects it into the body <b>10</b>. The thickening is reduced in diastole (before the heart is contracting) and increased in systole (when the heart is ejecting). This is seen easily by echocardiogram, and can be routinely measured.
In addition to the squeezing, there is a twisting of fibers that results in thickening of the ventricular wall, and shortening of the muscle from the base <b>35</b> to the apex <b>37</b>. This is the predominant aspect of left ventricle systole. The muscle untwists after twisting (when the heart is prepared to fill) during the first third of ventricular relaxation.
The twisting or writhing motion which begins at the apex <b>37</b> and rises toward the base <b>35</b>, as shown by the arrow <b>47</b>. The rising writhing motion occurs because the heart muscle fibers run in a circular or spiral direction around the heart <b>12</b>. When these fibers constrict, they cause the heart to twist initially at the small area of the apex <b>37</b>, but progressively and ultimately to the wide area of the base <b>35</b>.
Recent studies by MRI show that twisting in systole accounts for approximately 80% of stroke volume, while untwisting (in diastole) accounts for 80% of left ventricle filling. This twisting and untwisting occurs in the same muscle segments, as the ventricle shortens during ejection and lengthens after blood is ejected.
The amount of blood pumped from the left ventricle <b>25</b> divided by the amount of blood available to be pumped is referred to as the ejection fraction of the heart <b>12</b>. Generally, the higher the ejection fraction the more healthy the heart. A normal heart, for example, may have a total volume of one hundred milliliters and an ejection fraction of sixty percent. Under these circumstances, 60 milliliters of blood are pumped with each beat of the heart <b>12</b>. It is this volume of blood in the normal heart of this example, that is pumped with each beat to provide nutrients including oxygen to the muscles and other tissues of the body <b>10</b>.
The muscles of the body, of course, include the heart muscle or myocardium which defines the various chambers <b>18</b>-<b>25</b> of the heart <b>12</b>. This heart muscle also requires the nutrients and oxygen of the blood in order to remain viable. With reference to FIG. 2, it can be seen that the anterior or front side of the heart <b>12</b> receives oxygenated blood through a common artery <b>58</b> which bifurcates into a septal artery branch <b>52</b>, which is directed toward the septum <b>41</b>, and an anterior descending artery <b>54</b> which is directed toward the apex <b>37</b> and the lateral ventricle wall <b>38</b>.
The inferior wall <b>44</b> is supplied by the right coronary artery which also perfuses the septum <b>41</b>. This wall <b>44</b> forms a triangle which extends from the base <b>35</b> to the apex <b>37</b>. Consequently, the apex <b>37</b> is supplied by both the anterior descending artery and the right coronary artery.
When a blockage occurs in one of these coronary arteries, that portion of the heart muscle which is fed by the blocked artery no longer receives the oxygen needed to remain viable. These blockages typically occur in the common artery <b>50</b> and in the septal artery branch <b>52</b>. When the common artery is involved, the septum <b>41</b>, apex <b>37</b> and lateral wall <b>38</b> all become ischemic or oxygen deprived. When only the septal artery branch <b>52</b> is involved, the ischemic symptoms are limited primarily to the septum <b>41</b> and the apex <b>37</b>. In this latter case, the septum <b>41</b> is almost always affected, the apex <b>31</b> is usually affected, and the lateral wall <b>38</b> is sometimes affected.
As the ischemia progresses through its various stages, the affected myocardium dies losing its ability to contribute to the pumping action of the heart. The ischemic muscle is no longer capable of contracting so it cannot contribute to either squeezing or the twisting motion required to pump blood. This non-contracting issue is said to be akinetic. In severe cases the akinetic tissue, which is not capable of contracting, is in fact elastic so that blood pressure tends to develop a bulge or expansion of the chamber. This is particularly detrimental as the limited pumping action available, as the heart <b>12</b> loses even more of its energy to pumping the bulge instead of the blood.
The body's reaction to ischemic infarction is of particular interest. The body <b>10</b> seems to realize that with a reduced pumping capacity, the ejection fraction of the heart is automatically reduced. For example, the ejection fraction may drop from a normal sixty percent to perhaps twenty percent. Realizing that the body still requires the same volume of blood for oxygen and nutrition, the body causes its heart to dilate or enlarge in size so that the smaller ejection fraction pumps about the same amount of blood. As noted, a normal heart with a blood capacity of seventy milliliters and an ejection fraction of sixty percent would pump approximately 42 milliliters per beat. The body seems to appreciate that this same volume per beat can be maintained by an ejection fraction of only thirty-percent if the ventricle <b>25</b> enlarges to a capacity of 140 milliliters. This increase in volume, commonly referred to as “remodeling” not only changes the volume of the left ventricle <b>25</b>, but also its shape. The heart <b>12</b> becomes greatly enlarged and the left ventricle <b>25</b> becomes more spherical in shape losing its apex <b>37</b> as illustrated in FIG. <b>3</b>. In this view, the stippled area of cross section shows the ischemic or infracted region of the myocardium.
On the level of the muscle fibers, it has been noted that dilation of the heart causes the fibers to reorient themselves so that they are directed away from the inner heart chamber containing the blood. As a consequence, the fibers are poorly oriented to accomplish even the squeezing action as the lines of force become less perpendicular to the heart wall. It will be noted that this change in fiber orientation occurs as the heart dilates and moves from its normal elliptical shape to its dilated spherical shape. The spherical shape further reduces pumping efficiency since the fibers which normally encircle the apex to facilitate writhing are changed to a more flattened formation as a result of these spherical configurations. The resulting orientation of these fibers produce lines of force which are also directed laterally of the ventricle chamber <b>25</b>. Thus, the dilatation and resulting spherical configuration greatly reduce contraction efficiency. It also raises myocardial oxygen demands as torsional defamation (strain) increases. When a remote muscle is supplied by a non-occluded vessel under stress, the remote muscle tends to contract inefficiently.
Although the remodeling of the heart <b>12</b> by the body <b>10</b> helps in maintaining the blood flow, it places the heart wall under considerable stress which eventually can result in congestive heart failure. While myocardial ischemia or infarction is the primary cause of death and disability in this country, congestive heart failure is certainly the secondary cause with over 400,000 cases reported annually. It is this post-infarction congestive heart failure which is a primary focus of the present invention.
As noted, successful acute reprefusion by thrombolysis, percutaneous angioplasty, or urgent surgery can decrease early mortality by reducing arrhythmia and cardiogenic shock. These procedures applied in the early stages of ischemia can also aid in salvaging the epicardial surface of the myocardium and thereby prevent akinetic tissue from becoming dyskinetic. Notwithstanding these known methods of intervention, cardiac dilation and subsequent congestive heart failure occur in approximately fifty percent of the post-infarction patients.
Ventricular volume is not excessive or >100 ml/m<sup>2 </sup>left ventricular end systolic volume. The akinetic lateral wall may contain non-functional (contractile tissue) that is hibernating. This indicates viable tissue that improves contraction several months after complete revascularization or when ventricular volume is reduced to produce a more normal ventricular contour (i.e. ellipse). This recovery after revascularization can occur only when ventricular volume is not very large, or the left ventricular end systolic volume index >100 ml/m<sup>2</sup>. This aspect of recovery of akinetic hibernating muscle is potentially important when the ventricular shape is changed surgically to go from a sphere (failing heart) to a conical or apical (more normal configuration) contour.
The procedure of the present invention addresses the effects of myocardial infarction using a cardioprotective approach to restore the geometry of the left ventricle. This is not a “remodeling” procedure automatically produced by the body <b>10</b>, nor a “reconstructive” procedure which leaves the heart with other than a normal geometry. Rather, this is a procedure which attempts to “restore” the normal geometry, and particularly the apical configuration of the left ventricle <b>25</b>. The procedure reduces the volume of the left ventricle <b>25</b>, but also increases the percentage of the ventricle wall which is viable. This greatly increases the ejection fraction of the heart and significantly reduces heart stress.
With a primary purpose of reducing the left ventricle volume, the intent of the procedure initially is to remove that portion of the wall which is not capable of contracting. This, of course, includes the scarred dyskinetic segments, which are easy to visualize, but may also include akinetic segments, which do not contract despite their normal appearance.
An incision <b>61</b> is cut into the myocardial wall of the dilated heart <b>12</b> as illustrated in FIG. <b>4</b>. If the surrounding tissue is dyskinetic, it will typically be formed entirely of thin, elastic scar tissue. It is the elasticity of this scar tissue which causes the detrimental ballooning or bulging effects previous discussed.
In some cases, the tissue surrounding the incision <b>61</b> will be somewhat marbled as illustrated in FIG. 5 with patches of both scar tissue <b>63</b> and viable red tissue <b>65</b>. This marbled tissue is often characterized by trabeculae <b>67</b> which form ridges along the inner surface or endothelium of the wall. In spite of the presence of some viable tissue <b>65</b>, these marbled walls of the heart <b>12</b> may nevertheless be akinetic.
With reference to FIG. 6, it is apparent that the akinetic portion of the myocardium may even appear to be viable with an absence of white scar tissue and the presence of a full red color. Nevertheless, these portions are akinetic and offer no positive effect to the pumping process.
Given these factors, it is apparent that a determination as to where the akinetic portions begin and end cannot be a visual determination as relied on by the prior art. Although the visual appearance may be of some value in this determination, ultimately, one must palpate the tissue as illustrated in FIG. <b>7</b>. Note that this emphasizes the importance of performing the restorative surgery on a beating heart. By palpating the myocardial wall, one can feel where the contractions of the lateral ventricular wall <b>38</b> and the septum <b>41</b> begin and end. Without regard for color or other properties visually distinguishable, the palpating will usually indicate viable tissue on one side of an imaginary circumferential line <b>70</b>, with akinetic and dyskinetic tissue on the other side of the imaginary line <b>70</b>. As described in greater detail below, a patch <b>72</b> will ultimately be positioned relative to this imaginary circumferential line <b>70</b> not only to reduce the volume of the left ventricle <b>25</b> but also to define that reduced volume with a larger percentage of viable heart muscle.
After the preferred location of the patch <b>72</b> has been determined relative to the circumferential line <b>70</b>, a continuous Fontan stitch <b>74</b> can be placed in proximity to the line <b>70</b> as illustrated in FIG. <b>9</b>. This stitch <b>74</b> produces an annular protrusion <b>76</b> which forms a neck <b>78</b> relative to the imaginary line <b>70</b>. This neck <b>78</b> initially may have a round circular configuration as illustrated in FIG. <b>9</b>. However, as the suture <b>74</b> is tightened, the musculature of the myocardium will form a natural oval shape as illustrated in FIG. <b>1</b>. It is this oval-shaped neck <b>78</b>, formed by the Fontan stitch <b>74</b>, which in its natural ovoid shape is particularly adapted to receive the patch <b>72</b> of the present invention.
Providing the patch <b>72</b> with a configuration complimentary to the ovoid shape of the Fontan stitch <b>74</b> is believed to be of particular importance and advantage to the present invention. In the past, patches of a round, circular form were used. This form maintained the fibers in their less efficient transverse orientation. This was especially true of rigid and semi-rigid patches. As a result, the fiber contraction continued to be very inefficient. Providing the patch with an oval configuration restores the apex <b>37</b> or elliptical form of the heart <b>12</b>. On a muscle fiber level, the fibers are directed back to the more efficient 60 degree orientation which produces lines of force more perpendicular with respect to the heart wall <b>38</b>. This reorientation of the lines of forces greatly increases contraction efficiency.
Of perhaps equal concern is the use of semi-rigid or rigid rings on the patches of the past. By keeping the edges of the patch in a rigid configuration, these rings have inhibited the natural tendency of the heart to form the remaining muscle into a normal apical chamber.
Construction of various embodiments of the patch <b>72</b> are discussed with reference to FIGS. 12A-20. In the plan view of FIG. 12A, a sheet material <b>81</b> is illustrated to have the shape of an ellipse with a major axis 83 between 30 and 50 millimeters and a minor axis <b>85</b> between 20 and 30 millimeters. It is contemplated that the sheet material <b>81</b> can be provided in two sizes, such as 20×30 millimeters and 30×40 millimeters.
The sheet material <b>81</b> may be formed, for example, from Dacron (Hemoshield), or polytetrafluroethylene (Gortex). However in a preferred embodiment, the sheet material <b>81</b> is formed of autologous pericardium, or some other fixed mammalium tissue such as bovine or porcine pericardium. Importantly, the sheet material <b>81</b> is preferably sized and configured with a shape similar to that of the Fontan neck <b>78</b> as illustrated in FIG. <b>11</b>. As noted, this shape is non-circular and preferably oval.
The sheet material <b>81</b> can have a generally flat planar configuration, or can be shaped as a section of a sphere. The spherical shape can be achieved as illustrated in FIG. 12B by fixing the pericardium while it is stretched over a spherical die to form a concave surface <b>90</b>.
In addition to the sheet material <b>81</b>, the patch <b>72</b> also preferably includes a ring <b>87</b> which will typically have a toroidal configuration with a circumferential cross section that is circular, as shown in FIG. <b>13</b>. The ring will typically be formed of a plastic graft material that can also be made of curled autogenous tissue such as fascia or pericardium. In general, the ring <b>87</b> can be formed from any biocompatible material having a degree of flexibility suitable to prevent interference with the normal contractions of the heart <b>12</b>.
The circumferential cross section view of FIG. 14 illustrates that the ring <b>87</b> may be enclosed in a tubular sheath <b>88</b> which may be formed from woven Dacron, and incorporated to promote tissue ingrowth to the patch <b>72</b>.
The ring <b>87</b> will generally have a non-circular shape which may be similar to but smaller than the shape of the material <b>81</b>. Providing the ring <b>87</b> with a shape similar to the material <b>81</b> will enable the ring <b>87</b> to be attached to the material <b>81</b> as illustrated in FIGS. 15 and 16 with a body or internal oval <b>91</b> of the patch disposed within the ring <b>87</b>, and a circumferential rim or flange <b>93</b> disposed outwardly of the ring <b>87</b>. The rim <b>93</b> will preferably have a constant width around its circumference. This width will typically be in a range between 5 and 10 millimeters.
The internal oval <b>91</b> disposed within the ring <b>87</b> preferably has a substantially oval configuration with a major axis <b>92</b> and a minor axis <b>94</b>. In an alternative preferred embodiment of the invention, the body or internal oval <b>91</b> of the patch disposed within the ring <b>87</b> has a major axis of about 40 mm (4 cm) and a minor axis of about 10 mm (1 cm). The ratio of the major axis <b>92</b> to the minor axis <b>94</b> in this embodiment is about 4:1 or 4. The inventors have determined that a more linear, longitudinally elongated internal oval or body <b>91</b> makes the ventricular shape, after patch placement, more elliptical, making resulting fiber orientation oblique and directed towards a conical apex <b>37</b>. Although the preferred major axis to minor axis ratio in this embodiment of the patch is about 4:1, ratios greater than 2:1 are also desirable for making the apex <b>37</b> more elliptical. The major axis <b>92</b> preferably may vary between 20 mm (2 cm) and 80 mm (8 cm) and the minor axis preferably may vary between 5 mm (0.5 cm) and 10 mm (1 cm).
Many variations on the patch <b>72</b> will be apparent from the foregoing discussion. For example, as illustrated in FIG. 17, the sheet material <b>81</b> can be provided with a convex surface <b>95</b> facing the left ventricle <b>25</b> rather than the concave surface illustrated in FIG. <b>13</b>. As illustrated in FIGS. 16 and 18, the ring <b>87</b> can be disposed on either the interior or exterior side of the material <b>81</b>.
With reference to FIG. 18, the ring <b>87</b> can be attached to the material <b>81</b> by adhesive or by stitches <b>97</b> passing over the ring <b>87</b> and through the material <b>81</b>. Alternatively, with reference to FIG. 19, the ring <b>87</b> can be sandwiched between two pieces of the sheet material. In this case, a second piece of the sheet material <b>99</b> can be positioned on the side of the ring <b>87</b> opposite to the sheet material <b>81</b>. Appropriate sutures extending around the ring <b>87</b> and through the materials <b>81</b> and <b>99</b> will sandwich the ring and maintain it in the preferred position. With reference to FIG. 20, the second piece of material <b>99</b> can be formed as a circle with an inner diameter <b>100</b> less than that of the ring <b>87</b>, and an outer diameter <b>102</b> generally equal to that of the material <b>81</b>.
It will be appreciated that many variations on these preferred embodiments of the patch <b>82</b> will be apparent, each having a generally non-circular sheet material, such as the material <b>81</b>, and perhaps a somewhat flexible toroid or oval ring <b>87</b>.
In a preferred method for placing the patch <b>72</b>, interrupted sutures <b>105</b> can be threaded through the Fontan neck <b>78</b> as illustrated in FIG. <b>21</b>. Where the tissue is soft, the sutures <b>105</b> can be looped through pledgets <b>110</b> on the interior side of the neck <b>78</b> with the free ends of the sutures <b>105</b> extending through the exterior side of the neck <b>78</b>. These free ends, emanating from progressive positions around the circumferential neck <b>78</b>, are passed in complementary positions through the body of the patch <b>72</b> which is initially positioned remotely of the neck <b>78</b> as illustrated in FIG. <b>21</b>. Since the Fontan stitch <b>74</b> may be applied to normal (although akinetic) tissue, the pledgets <b>110</b> are preferred to insure that the sutures <b>105</b> are well anchored in the neck <b>78</b>.
Another method for placement of the interrupted patch suture is illustrated in FIGS. 22A and 22B. In this view, which is similar to FIG. 21, interrupted sutures <b>111</b> are directed through the entire ventricular wall <b>38</b> and exit the wall <b>38</b> in proximity to the protrusion <b>76</b> which forms the Fontan neck <b>78</b>. These sutures <b>111</b> can also be anchored in a pledged strip <b>113</b> disposed on the outer surface of the heart <b>12</b> to further enhance the anchoring of these sutures <b>111</b>.
When all of the interrupted sutures <b>105</b> have been placed around the circumference of the neck <b>87</b>, the patch <b>72</b> can be moved from its remote location along the sutures <b>105</b> and into proximity with the oval neck <b>78</b>. This step is illustrated in FIG. 22A where the patch <b>72</b> is embodied with the concave surface <b>90</b> facing the neck <b>78</b> and with the ring <b>87</b> disposed outwardly of the material <b>81</b>. After the patch <b>72</b> has been moved into an abutting relationship with the neck <b>78</b>, the interrupted sutures <b>105</b> can be tied as illustrated in FIG. <b>23</b>.
Having closed the left ventricular cavity <b>25</b> with the patch <b>72</b>, one may proceed to address any bleeding which may have resulted from placement of the Fontan stitch <b>74</b> or the sutures <b>105</b>, especially from the region of the septum <b>41</b>. Such bleeding, illustrated by the reference numeral <b>112</b> in FIG. 23, will typically occur in close proximity to the neck <b>78</b> and beneath the region covered by the rim or flange <b>93</b> associated with the material <b>81</b> of the patch <b>72</b>. This bleeding can normally be stopped by merely placing a suture through the ventricular wall <b>38</b> and the rim <b>93</b> at the point of bleeding. A pledget <b>114</b> can be used to tie the suture <b>105</b> with the rim <b>93</b> closely held against the bleeding wall <b>38</b>. This reinforcing stitch, acting in combination with the rim <b>93</b> of the patch <b>72</b>, will usually stop any bleeding associated with the sutures.
In the embodiment of the patch where the internal oval <b>91</b> is more linear or longitudinally elongated (e.g., 10×40 mm internal oval), the method of patch closure produces an oblique line. The lower margin is at the apex, adjacent to the right or apical side of the anterior papillary muscle. The closure extends from the lateral ventricle toward the septum, that progressed along an intraventricular line to approximately 2 cm below the aortic valve on the septum. The open width of the patch is ˜1 cm (within the oval) so that the suture which runs along the patch margins can be used for hemostasis.
With the patch <b>72</b> suitably placed, the operative site can be closed by joining the myocardial walls in a vest-over-pants relationship as illustrated in FIG. <b>24</b>. Care should be taken not to distort the right ventricle <b>21</b> by folding the septum wall <b>41</b> over the ventricular wall <b>38</b>. Alternatively, the lateral wall <b>38</b> can be disposed interiorly of the septum wall <b>41</b> so a majority of the force on the patch <b>72</b> is diverted to the lateral wall <b>38</b>. These walls <b>38</b> and <b>41</b> can be overlapped in close proximity to the patch <b>72</b> in order to avoid creating any cavity between the patch <b>72</b> and the walls <b>38</b>, <b>41</b>. When air evacuation is confirmed by transesophageal echo, the patient can be weaned off bypass usually with minimal, if any, inotropic support. Decanulasation and closure is routine.
FIG. 24 is positioned in proximity to FIG. 3 in order to illustrate the dramatic difference between the pre-operative dilated heart of FIG. <b>3</b> and the post-operative apical heart of FIG. <b>24</b>. For comparison it will again be noted that the dilated heart of FIG. 3 might typically have a left ventricular volume of 140 milliliters which might produce a blood flow of 42 milliliters with an ejection fraction of 30%. Comparing this with the postoperative heart of FIG. 24, it can be seen initially that the ventricular volume is reduced for example to 90 milliliters. The percentage of viable heart wall as opposed to akinetic heart wall is greatly increased thereby providing an increase in the ejection fraction, for example from thirty percent to forty-five percent. This combination results in a pumped blood volume of about 40 milliliters with each beat of the heart <b>12</b>.
These structural changes are somewhat quantitative in consideration. But a further advantage, qualitative in nature, is also associated with the present procedure. It will be noted that this restorative procedure provides the heart <b>12</b> with a more natural apical configuration which facilitates the writhing action discussed with reference to the arrow <b>47</b> in FIG. <b>1</b>. Thus, not only is the normal size of the heart achieved, but the restoration procedure also achieves a normal heart operation. In combination, the patch <b>72</b> and the resulting procedure significantly reduce the long term effects of myocardial ischemia and overcome many of the causes associated with congestive heart failure.
It may be found that muscle function will be restored to some remote areas following the altered ventricular architecture. Although not fully understood, it is believed that this restoration procedure improves remote segmental myocardial contractility by reducing the wall tension and stress in the myocardium due to a reduction in ventricular volume. The stress equation states that <maths><math><mrow><mi>Stress</mi><mo>=</mo><mfrac><mrow><mi>P</mi><mo>×</mo><mi>R</mi></mrow><mrow><mn>2</mn><mo></mo><mi>h</mi></mrow></mfrac></mrow></math><img id="EMI-M00001" file="US06544167-20030408-M00001.TIF" img-content="math" img-format="tif" alt="embedded image" /><attachments><attachment idref="MATHEMATICA-00001" attachment-type="nb" file="US06544167-20030408-M00001.NB" /></attachments></maths>
where
P is blood pressure;
R is radius of the heart wall; and
h is wall thickness.
The late recovery of hibernating muscle, which may be present in akinetic muscle whose fiber orientation is directed helically (toward the newly created apex). This progressive shape change may provide further improvement in contractile function several months after restoration. Reducing the ventricular volume decreases the radius, increases the thickness, and thereby reduces wall stress. This improves the myocardial oxygen supply/demand relationship, but may also revive the contractibility of otherwise normal but previously stressed myocardium. At the very least, the reduced stress on the heart <b>12</b> is relieved along with any potential for congestive heart failure.
A further advantages of this procedure relates to the incision <b>61</b> in the left ventricle <b>25</b> which also provides access to the mitral valve <b>34</b>. Replacing this mitral valve <b>34</b> through the left ventricle <b>25</b> is much simpler than the present intra-atrial replacement procedure. Coronary artery bypass grafts also can be more easily accommodated intraoperatively. As a result, all of these repairs can be undertaken with greater simplicity and reduced time. While blood cardioplegia may be advantageously used for revascularization and valvular procedures, it would appear that the restorative procedure is best accomplished with continuous profusion of the beating open heart for cardiac protection.
Placement of patch <b>72</b> can be further enhanced by providing in the patch kit a plurality of sizing disks which can be individually held in proximity to the Fontan neck in order to determine appropriate patch size. Similar discs, triangular in shape may be used for the inferior restoration process. The disks might have a generally planar configuration, and of course, would vary in size. Each disk might have a centrally located handle extending from the planar disk for ease of use. The patch <b>72</b> could be removably mounted on a holder also including a disk, on which the patch is mounted, and an elongate handle extending from the disk to facilitate placement.
As further support for the restoration procedure, a special suture needle is contemplated which has a proximal end and a distal end. The proximal end is generally straight and accounts for more than half of the length of the needle. The distal end is curved along a relatively large radius facilitating initial penetration of the thick heart wall. With this configuration, the needle can be easily introduced through the thick myocardium, but then pulled along a generally straight path as it is removed interiorly of the ventricle.
The goal of these procedures is to restore the heart <b>12</b> to its normal size, shape and function. This includes restoring the conical apex of the heart in order to achieve the writhing pumping action. The nonfunctioning segmental ventricular myocardium is excluded and replaced with a patch so that the only akinetic wall of the ventricle is that defined by the small patch area. Not only is visual assessment enhanced, but more importantly, palpation affords the surgeon the ability to carefully and accurately determine the circumferential line of separation between the contracting and noncontracting muscle. This determination is achieved although the muscle may have normal color and may not contain either circular or trabecular scar tissue.
It is believed that cardioplegia arrest maybe deleterious to ventricular function in the open ventricle because of nonuniform flow distribution. By avoiding this cardioplegia arrest and operating on a beating heart, aortic cross clamping as well as the use of inter-aortic balloons and ventricular assist devices can be avoided. Patch placement can be intraoperatively adjusted guided by echo or radio nucleotide data. Placement of the patch is further simplified by creation of the Fontan neck <b>78</b>, and use of interrupted felt or pericardial pledgeted sutures <b>105</b>. The circumferential rim <b>93</b> associated with the patch <b>72</b> facilitates bleeding control without distortion of the patch <b>72</b>. Finally, using a vest-over-pants closure of the excluded ventricle obliterates dead space and provides security against patch leaks and resultant expansion between the site of closure of the ejecting ventricle with the patch, and where the excluded muscle is closed by the excluded ventricle.
If the patch has a conical or elliptical contour, the pants-over-vest closure is excluded, so that progressive recovery of potentially hibernating muscle (previously akinetic) can occur so that the muscle itself forms the apex. The pants-over-vest closure may prevent this, and that is the reason for excluding it.
Within these wide objectives and parameters, there will be variations on the structure of the patch and the methods of restoration. Although the non-circular configuration of the sheet material and ring are believed to be critical, the shape of the patch <b>72</b> may vary widely to provide the best anatomical fit with the natural shape of the ventricle <b>25</b>. The sheet material <b>81</b> may be composed of a variety of materials, both natural and artificial. These materials may be woven or nonwoven to achieve a desired structure for the sheet material <b>81</b>. The ring <b>87</b> may similarly be formed from a variety of materials and provided with a variety of shapes in order to add structure to the patch <b>72</b> without interfering with the normal contractions of the heart <b>12</b>. Variations of the steps of the associated restoration method might include mounting the patch with a convex surface facing the ventricular cavity, use of tissue adhesives are also contemplated for attaching sealing and otherwise fixing the patch <b>72</b> to the Fontan neck <b>78</b>.
Given these wide variations, which are all within the scope of this concept, one is cautioned not to restrict the invention to the embodiments which have been specifically disclosed and illustrated, but rather encouraged to determine the scope of the invention only with reference to the following claims.
Contents4
14 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14
Every citation, both waysCites: the store holds 37 of 38
| Document | Relation | Office | Cited during |
|---|---|---|---|
| US10512542B2 | Cited by | United States of America | Applicant |
| US8888843B2 | Cited by | United States of America | Applicant |
| US12004937B1 | Cited by | United States of America | Applicant |
| US10500048B2 | Cited by | United States of America | Applicant |
| US11497606B2 | Cited by | United States of America | Applicant |
| US10653524B2 | Cited by | United States of America | Applicant |
| US7914438B2 | Cited by | United States of America | Applicant |
| US9403329B2 | Cited by | United States of America | Applicant |
| US10470883B2 | Cited by | United States of America | Applicant |
| US9649211B2 | Cited by | United States of America | Applicant |
| US9610163B2 | Cited by | United States of America | Applicant |
| US6702763B2 | Cited by | United States of America | Search report |
| US10595985B2 | Cited by | United States of America | Applicant |
| WO2012033977A1 | Cited by | World Intellectual Property Organization (WIPO) | Applicant |
| US6959711B2 | Cited by | United States of America | Applicant |
| US11999837B2 | Cited by | United States of America | Applicant |
| US12150856B2 | Cited by | United States of America | Applicant |
| US11672659B2 | Cited by | United States of America | Applicant |
| US2007129598A1 | Cited by | United States of America | Pre-grant |
| US10123874B2 | Cited by | United States of America | Applicant |
| US11534302B2 | Cited by | United States of America | Applicant |
| US11648119B2 | Cited by | United States of America | Applicant |
| US2008177130A1 | Cited by | United States of America | Pre-grant |
| US2005065396A1 | Cited by | United States of America | Pre-grant |
| US11622759B2 | Cited by | United States of America | Applicant |
| US2003181940A1 | Cited by | United States of America | Pre-grant |
| US11648120B2 | Cited by | United States of America | Applicant |
| US2009275976A1 | Cited by | United States of America | Pre-grant |
| US10376365B2 | Cited by | United States of America | Applicant |
| US10478303B2 | Cited by | United States of America | Applicant |
| US2006064175A1 | Cited by | United States of America | Pre-grant |
| US12109116B2 | Cited by | United States of America | Applicant |
| US2002133227A1 | Cited by | United States of America | Pre-grant |
| US2008161825A1 | Cited by | United States of America | Pre-grant |
| US7320665B2 | Cited by | United States of America | Applicant |
| US2008215074A1 | Cited by | United States of America | Pre-grant |
| US10702386B2 | Cited by | United States of America | Applicant |
| US11896472B2 | Cited by | United States of America | Applicant |
| US10166098B2 | Cited by | United States of America | Applicant |
| US6681773B2 | Cited by | United States of America | Search report |
| US2002173694A1 | Cited by | United States of America | Pre-grant |
| US2015018946A1 | Cited by | United States of America | Pre-grant |
| US2014046442A1 | Cited by | United States of America | Pre-grant |
| US2010081869A1 | Cited by | United States of America | Pre-grant |
| US8845717B2 | Cited by | United States of America | Applicant |
| US11419722B2 | Cited by | United States of America | Applicant |
| US11857403B2 | Cited by | United States of America | Applicant |
| WO2019197353A1 | Cited by | World Intellectual Property Organization (WIPO) | Applicant |
| US12285336B2 | Cited by | United States of America | Applicant |
| US7485088B2 | Cited by | United States of America | Applicant |
| US11678986B2 | Cited by | United States of America | Applicant |
| US9549804B2 | Cited by | United States of America | Applicant |
| US11207167B2 | Cited by | United States of America | Search report |
| US11160656B2 | Cited by | United States of America | Applicant |
| EP3058878A1 | Cited by | European Patent Office (EPO) | Applicant |
| US11298229B2 | Cited by | United States of America | Applicant |
| US12458341B2 | Cited by | United States of America | Applicant |
| US12478474B2 | Cited by | United States of America | Applicant |
| US2002133182A1 | Cited by | United States of America | Pre-grant |
| US9592118B2 | Cited by | United States of America | Applicant |
| US2005278024A1 | Cited by | United States of America | Pre-grant |
| US10918471B2 | Cited by | United States of America | Applicant |
| US2003198919A1 | Cited by | United States of America | Pre-grant |
| US2006199995A1 | Cited by | United States of America | Pre-grant |
| US12465489B2 | Cited by | United States of America | Applicant |
| US2008319256A1 | Cited by | United States of America | Pre-grant |
| US12295845B2 | Cited by | United States of America | Applicant |
| US8298290B2 | Cited by | United States of America | Applicant |
| US2006009799A1 | Cited by | United States of America | Pre-grant |
| US10092427B2 | Cited by | United States of America | Applicant |
| US10251635B2 | Cited by | United States of America | Applicant |
| US11426279B2 | Cited by | United States of America | Applicant |
| US2004243229A1 | Cited by | United States of America | Pre-grant |
| US2004249408A1 | Cited by | United States of America | Pre-grant |
| US10092384B2 | Cited by | United States of America | Applicant |
| US7341584B1 | Cited by | United States of America | Applicant |
| US11759321B2 | Cited by | United States of America | Applicant |
| US2003192561A1 | Cited by | United States of America | Pre-grant |
| US2006137697A1 | Cited by | United States of America | Pre-grant |
| US12350153B2 | Cited by | United States of America | Applicant |
| US9763770B2 | Cited by | United States of America | Applicant |
| US12419747B2 | Cited by | United States of America | Applicant |
| US10039857B2 | Cited by | United States of America | Applicant |
| US11974921B2 | Cited by | United States of America | Applicant |
| US11464634B2 | Cited by | United States of America | Applicant |
| US11413145B2 | Cited by | United States of America | Applicant |
| US12171647B2 | Cited by | United States of America | Applicant |
| US9592121B1 | Cited by | United States of America | Applicant |
| US2005017333A1 | Cited by | United States of America | Pre-grant |
| US11000372B2 | Cited by | United States of America | Applicant |
| US6994093B2 | Cited by | United States of America | Applicant |
| US8007428B2 | Cited by | United States of America | Applicant |
| US3279464A | Cites | United States of America | Applicant |
| US3656185A | Cites | United States of America | Applicant |
| US3874388A | Cites | United States of America | Applicant |
| US3983863A | Cites | United States of America | Applicant |
| US4042979A | Cites | United States of America | Applicant |
| US4055861A | Cites | United States of America | Applicant |
| US4164046A | Cites | United States of America | Applicant |
| US4204283A | Cites | United States of America | Applicant |
40 members in 9 offices
Priority claims10
| Document | Office | Kind | Date |
|---|---|---|---|
| 7181798 | United States of America | A | |
| 7181798 | United States of America | A | |
| 48175500 | United States of America | A | |
| 48175500 | United States of America | A | |
| 86069901 | United States of America | A | |
| 09071817 | – | – | – |
| 09481755 | – | – | – |
| US19980071817 | – | – | – |
| US20000481755 | – | – | – |
| US20010860699 | – | – | – |
Members40
| Document | Office | Kind | |
|---|---|---|---|
| CA2330746A1 | Canada | A1 | |
| WO9956655A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU2570599A | Australia | A | |
| US6024096A | United States of America | A | |
| WO0042919A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU3212600A | Australia | A | |
| EP1075227A1 | European Patent Office (EPO) | A1 | |
| US6221104B1 | United States of America | B1 | |
| EP1148821A1 | European Patent Office (EPO) | A1 | |
| US2002026092A1 | United States of America | A1 | |
| US6439237B1 | United States of America | B1 | |
| US6450171B1 | United States of America | B1 | |
| US2002198603A1 | United States of America | A1 | |
| US6544167B2This record | United States of America | B2 | |
| JP2003517330A | Japan | A | |
| US2003191538A1 | United States of America | A1 | |
| US2004015046A1 | United States of America | A1 | |
| US2004181126A1 | United States of America | A1 | |
| US6837247B2 | United States of America | B2 | |
| US2005119520A1 | United States of America | A1 | |
| CA2330746C | Canada | C | |
| US7056280B2 | United States of America | B2 | |
| US2006258900A1 | United States of America | A1 | |
| JP3876343B2 | Japan | B2 | |
| EP1075227A4 | European Patent Office (EPO) | A4 | |
| US7275546B2 | United States of America | B2 | |
| EP1148821B1 | European Patent Office (EPO) | B1 | |
| DE60037182D1 | Germany | D1 | |
| US2008097147A1 | United States of America | A1 | |
| ES2296608T3 | Spain | T3 | |
| DE60037182T2 | Germany | T2 | |
| EP1075227B1 | European Patent Office (EPO) | B1 | |
| AT425718T | Austria | T | |
| ATE425718T1 | Austria | T1 | |
| DE69940596D1 | Germany | D1 | |
| ES2322107T3 | Spain | T3 | |
| US7594886B2 | United States of America | B2 | |
| US2010081869A1 | United States of America | A1 | |
| US7758494B2 | United States of America | B2 | |
| US7914438B2 | United States of America | B2 |
38 transactions on the USPTO file
Allowed after 1 non-final rejection.
- Non-final rejections
- 1
- Final rejections
- 0
- RCEs
- 0
- Appeals
- 0
Over time
Point at a mark for the transactionTransactions
| Event | Code | |
|---|---|---|
| Expire PatentEXP. | EXP. | |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27SMAL | SMAL | |
| Recordation of Patent Grant MailedPGM/ | PGM/ | |
| Patent Issue Date Used in PTA CalculationAllowedPTAC | PTAC | |
| Issue Notification MailedAllowedWPIR | WPIR | |
| Receipt into PubsR1021 | R1021 | |
| Application Is Considered Ready for IssuePILS | PILS | |
| Receipt into PubsR1021 | R1021 | |
| Issue Fee Payment VerifiedN084 | N084 | |
| Workflow - Drawings FinishedDRWF | DRWF | |
| Workflow - Drawings Matched with File at ContractorDRWM | DRWM | |
| Amendment after Notice of Allowance (Rule 312)AllowedA.NA | A.NA | |
| Workflow - Drawings Received at ContractorDRWI | DRWI | |
| Workflow - Drawings Sent to ContractorDRWR | DRWR | |
| Issue Fee Payment ReceivedIFEE | IFEE | |
| Workflow - File Sent to ContractorSENT | SENT | |
| Receipt into PubsR1021 | R1021 | |
| Dispatch to PublicationsD1220 | D1220 | |
| Mail Notice of AllowanceAllowedMN/=. | MN/=. | |
| Notice of Allowance Data Verification CompletedAllowedN/=. | N/=. | |
| Interview Summary RecordEXIN | EXIN | |
| Date Forwarded to ExaminerFWDX | FWDX | |
| Correspondence Address ChangeC.AD | C.AD | |
| Change in Power of Attorney (May Include Associate POA)PA.. | PA.. | |
| Response after Non-Final ActionA... | A... | |
| Interview Summary RecordEXIN | EXIN | |
| Mail Non-Final RejectionNon-final rejectionMCTNF | MCTNF | |
| Non-Final RejectionNon-final rejectionCTNF | CTNF | |
| Case Docketed to Examiner in GAUDOCK | DOCK | |
| Application Dispatched from OIPEOIPE | OIPE | |
| Application Is Now CompleteCOMP | COMP | |
| Notice Mailed--Application Incomplete--Filing Date AssignedINCD | INCD | |
| Correspondence Address ChangeC.AD | C.AD | |
| IFW Scan & PACR Auto Security Review | – | |
| Preliminary AmendmentA.PE | A.PE | |
| Information Disclosure Statement (IDS) Filed | – | |
| Information Disclosure Statement (IDS) Filed | – | |
| Initial Exam Team nnIEXX | IEXX |
9 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Lapsed due to failure to pay maintenance feeLapsedFP | FP | |
| Information on status: patent discontinuationPATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362STCH | STCH | |
| Information on status: patent discontinuationPATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362STCH | STCH | |
| Lapse for failure to pay maintenance feesLapsedLAPS | LAPS | |
| Maintenance fee reminder mailedREMI | REMI | |
| Fee paymentFPAY | FPAY | |
| Fee payment procedurePAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: SMALL ENTITYFEPP | FEPP | |
| Fee paymentFPAY | FPAY | |
| AssignmentAS | AS |
Numbers
- Publication, DOCDB
- 6544167
- Publication, EPODOC
- US6544167
- Application
- 9860699
- Application, DOCDB
- 86069901
- Application, EPODOC
- US20010860699
Titles
- English
- Ventricular restoration patch
Patent term adjustment
- Applicant delay
- −120 days
- Net adjustment
- 0 days
Classification
- CPC, 4
- A61F2/2478
- A61F2/2445
- A61F2/2481
- A61F2/2487
- IPC, 2
- A61F2 00
- A61F2 24
- USPC, 4
- 600037000
- 600016000
- 606151000
- 623011110